No Data
Express News | Star market in vitro diagnostic company performance is showing a clear warming trend.
Sansure Biotech's Q3 Profit Plunges 81%
sansure biotech inc. (688289): Continuously high-speed growth, looking forward to the peak performance of the respiratory tract testing business season.
Event: Sansure Biotech Inc. released its 2024 third-quarter performance report, with the company continuing the high-speed growth momentum from the first half of the year. In the first three quarters of 2024, the company achieved revenue of 1.033 billion yuan, a year-on-year increase of 63.24%.
Shengxiang Biology: Shengxiang Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Shengxiang Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Express News | R&D investment accounts for 22.83% of revenue. Sansure Biotech Inc.'s non-GAAP net profit for the first three quarters increased by more than six times.
No Data
No Data